Long-term follow-up of de novo myelodysplastic syndromes treated with intensive chemotherapy: Incidence of long-term survivors and outcome of partial responders

British Journal of Haematology

Volumn 98, Issue 4, 1997, Pages 983-991

  Wattel, Eric ^a   De Botton, Stéphane ^a   Laï, Jean Luc ^b   Preudhomme, Claude ^c   Lepelley, Pascale ^c   Bauters, Francis ^a   Fenaux, Pierre ^a,c  

^a Service des Maladies du Sang   (France)

^b Lab de Cytogénétique Hop Andre Mignot R de Versailles   (France)

^c LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

Intensive chemotherapy; Myelodysplastic syndromes

Indexed keywords

AMSACRINE; CYCLOPHOSPHAMIDE; CYTARABINE; METHYLGLYOXAL; MITOXANTRONE; QUININE; VINCRISTINE; ZORUBICIN;

ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 0030863308     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.1997.2973114.x     Document Type: Article

References (45)

1. Anderson, J.E., Appelbaum, F.R., Fisher, L.D., Schoch, G., Shulman, H., Anasetti, C., Bensinger, W.I., Bryant, E., Buckner, C.D., Doney, K., Martin, P.J., Sanders, J.E., Sullivan, K.M., Thomas, E.D., Witherspoon, R.P., Hansen, J.A. & Storb, R. (1993) Allogeneic bone marrow transplantation for 93 patients with myelodysplastic syndrome. Blood, 82, 677-681.
2. Aul, C., Gattermann, N. & Schneider, W. (1995a) Epidemiological and etiological aspects of myelodysplastic syndromes. Leukemia and Lymphoma, 16, 247-262.
3. Aul, C., Runde, V., Gattermann, N., Germing, U. & Schneider, W. (1994) Treatment of advanced primary myelodysplastic syndromes with AML-type chemotherapy: results in 76 patients. (Abstract). Leukemia Research, 18, (Suppl.), 22.
4. Aul, C., Runde, V., Germing, U., Burk, M., Heyll, A., Hildebrandt, B. & Willers, R. (1995b) Remission rates, survival and prognostic factors in 94 patients with advanced MDS treated with intensive chemotherapy. Annals of Hematology, 70, (Suppl. 2), A138.
5. Bennett, J., Catovsky, D., Daniel, M.T., Flandrin, G., Galton, D., Gralnick, H. & Sultan, C. (1982) Proposals for the classification of myelodysplastic syndromes. British Journal of Haematology, 51, 189-199.
6. Bernstein, S., Brunetto, V., Davey, F., Mayer, R.J., Wurster-Hill, D., Schiffer, C. & Bloomfield, C. (1993) Intensive chemotherapy for patients with myelodysplastic syndromes. Blood, 82, (Suppl. 1), 1960.
7. Bishop, J.F. (1997) The treatment of adult myeloid leukaemia. Seminars in Oncology, 24, 57-69.
8. Cheson, B.D., Jasperse, D.M., Simon, R. & Friedman, M.A. (1986) A critical appraisal of low-dose Ara C in patients with acute non-lymphocytic leukemia and myelodysplastic syndromes. Journal of Clinical Oncology 4, 1857-1864.
9. De Witte, T., Muus, P., De Pauw, B. & Haanen, C. (1990) Intensive antileukemic treatment of patients younger than 65 years with myelodysplastic syndromes and secondary acute myelogenous leukemia. Cancer, 66, 831-837.
10. De Witte, T., Suciu, S., Boogaerts, M., Labar, B., Archimbaud, E., Runde, V., Selleslag, D., Zittoun, R., van der Lelie, J., Muus, R. DeMuynck, H., Dardenne, M., Willemze, R., Gratwohl, A. & Apperley, J. (1995a) Intensive remission-induction chemotherapy followed by autologous or allogenic stem cell transplantation (SCT) for high risk MDS and AML secondary to MDS (sAML) in patients < 60 years: a joint study of the EORTC LCG and the EBMT. Blood, 86, (Suppl. 1), 618a.
11. De Witte, T., Suciu, S., Peetermans, M., Fenaux, P., Strijckmans, P., Hayat, M., Jaksic, J., Selleslag, D., Zittoun, R., Dardenne, M., Solbu, G., Zwierzina, H. & Muus, P. (1995b) A pilot study of intensive chemotherapy for bad prognosis myelodysplasia (MDS) and secondary acute myeloid leukemia (sAML) following MUS of more than 6 months duration. A study by the Leukemia Cooperative Group of the European Organisation for Research and Treatment in Cancer (EORTC-LCG). Leukemia, 9, 1805-1811.
12. Demuynck, H., Delforge, M., Verhoef, G.E.G., Zachee, P., Vandenberghe, P., Van Den Berghe, H. & Boogaerts, M.A. (1996) Feasibility of peripheral blood progenitor cell harvest and transplantation in patients with poor-risk myelodysplastic syndromes. British Journal of Haematology, 92, 351-359.
13. Estey, E.H., Kantarjian, H.M., O'Brien, S., Kornblau, S., Andreeff, M., Beran, M., Pierce, S. & Keating, M. (1995) High remission rate, short remission duration in patients with refractory anemia with excess blasts (RAEB) in transformation (RAEB-t) given acute myelogenous leukemia (AML)-type chemotherapy in combination with granulocyte-CSF (G-CSF). Cytokines and Molecular Therapy, 1, 21-28.
14. Estey, E., Thall, P., Andreeff, M., Beran, M., Kantarjian, H., O'Brien, S., Escudier, S., Roberston, L.E., Koller Kornbla, S., Pierce, S., Freireich, E., Deisseroth, A. & Keating, M. (1994) Use of granulocyte colony-stimulating factor before, during, and after fludarabine plus cytarabine induction therapy of newly diagnosed acute myelogenous leukaemia or myelodysplastic syndromes: comparison with fludarabine plus cytarabine without granulocyte colony-stimulating factor. Journal of Clinical Oncology, 12, 671-678.
15. Farrow, A., Jacobs, A. & West, R.R. (1989) Myelodysplasia, chemical exposure, and other environnemental factors. Leukemia, 3, 33-35.
16. Fenaux, P. (1996) Myelodysplastic syndromes. Hematology and Cell Therapy, 38, 363-380.
17. Fenaux, P., Morel, P., Rose, C., Lai, J.L., Jouet, J.P. & Bauters, F. (1991) Prognostic factors in adult de novo myelodysplastic syndromes treated by intensive chemotherapy. British Journal of Haematology, 77, 497-501.
18. Fenaux, P., Preudhomme, C. & Hebbar, M. (1992) The role of intensive chemotherapy in myelodysplastic syndromes. Leukemia and Lymphoma, 8, 43-49.
19. Gajewski, J.L., Ho, W.G., Nimer, S.D., Hirji, K.F., Gekelman, L., Jacobs, A.D. & Champlin, R.E. (1989) Efficacy of intensive chemotherapy for acute myelogenous leukaemia associated with a preleukaemic syndrome. Journal of Clinical Oncology, 7, 1637-1645.
20. Ganser, A. & Hoelzer, D. (1992) Treatment of myelodysplastic syndromes with hematopoietic growth factors. Hematology/ Oncology Clinics of North America, 6, 633-653.
21. Gardin, C., Chaibi, P., de Revel, T., Rousselot, P., Turlure, P., Micléa, J.M., Nédellec, G. & Dombret, H. (1997) Intensive chemotherapy with idarubicin, cytosine arabinoside, and granulocyte colony-stimulating factor (G-CSF) in palients with secondary and therapy-related acute myelogenous leukemia. Leukemia, 11, 16-21.
22. Gobbi, M., Clavio, M., Miglino, M., Carrara, P., Gatti, A.M., Balleari, E., Cerri, R., Bruni, R., Pierri, I., Canepa, L., Celesti, L., Vallebella, E., Cavaliere, M., Pietrasanta, D., Ghio, K. & Damasio, E. (1996) Fludarabine, ARA-C, G-CSF with or without mitoxantrone (Flang-Flag) are tolerable and effective in bad prognosis acute myeloid leukaemia patients. (Abstract). British Journal of Haematology, 93, (Suppl. 2), 221.
23. Gore, S.D. & Burke, P.J. (1995) Long-term survival of subsets of patients with advanced myelodysplastic syndromes (MDS) treated with intensive chemotherapy. (Abstract). Blood, 86, (Suppl. 1), 339a.
24. Hellström-Lingberg, E., Robert, K.H., Gahrton, G. & Lindberg, G. (1992) A predictive model for the clinical response to low-dose Ara C: a study of 102 patients with myelodysplastic syndromes or acute leukaemia. British Journal of Haematology, 81, 503-511.
25. Hiddemann, W., Büchner, T., Wörmann, B., Koch, P., Aul, C., Balleisen, L. & Bennet, J. (1995) Intensive therapy of high risk myelodysplastic syndromes with sequential intermediate dose cytosine arabinoside and mitoxantrone with or without GM-CSF. (Abstract). Annals of Hematology, 70, (Suppl. II), A109.
26. Hirst, W.J. & Muffi, G.J. (1994) The rate of disease progression predicts the quality of remissions following intensive chemotherapy of myelodysplastic syndromes. Leukemia Research, 18, 797-804.
27. Hoyle, C.F., De Bastos, M., Wheatley, K., Sherrington, P.D., Fischer, P.J., Rees, J.K.H., Gray, R. & Hayhoe, F.G.J. (1989) AML associated with previous cytotoxic therapy. MDS or myeloproliferative disorders: results from the MRC's 9th AML trial. British Journal of Haematology, 72, 45-53.
28. Laporte, J.P., Isnard, F., Lesage, S., Fenaux, P., Douay, L., Lopez, M., Slachowiak, J., Najman, A. & Gorin, N.C. (1995) Autologous bone marrow transplantation with marrow purged by mafosfamide in seven patients with myelodysplastic syndromes in transformation (AML-MDS): a pilot study. Leukemia, 7, 2030-2033.
29. Levine, E.G. & Bloomfield, C.D. (1992) Leukemias and myelodysplastic syndromes secondary to drug, radiation and environmental exposure. Seminars in Oncology, 19, 47-84.
30. Martiat, P., Ferrant, A., Michaux, J.L. & Sokal, G. (1988) Intensive chemotherapy for acute non-lymphoblastic leukemia after primary myelodysplastic syndrome. Hematological Oncology 6, 299-305.
31. Michels, S.D., McKenna, R.W., Arthur, D.C. & Brunning, R.D. (1985) Therapy related acute myeloid leukemia and myelodysplastic syndrome: a clinical and morphologic study of 65 cases. Blood, 65, 1364-1372.
32. Michels, S.D., Saumur, J., Arthur, D.C., Robison, L.L. & Brunning, R.D. (1989) Refractory anemia with excess of blasts in transformation: hematological and clinical study of 52 patients. Cancer, 64, 2340-2346.
33. Miller, K.B., Kyungmann, K., Morrison, F.S., Winter, J.N., Bennett, J.M., Neiman, R.S., Head, D.R., Gassileth, P.A. & O'Connell, M.J. (1992) The evaluation of low dose cytarabine in the treatment of myelodysplastic syndromes: a phase III intergroup study. Annals of Hematology 65, 162-168.
34. Morel, P., Hebbar, M., Lai, J.L., Duhamel, A., Preudhomme, C., Wattel, E., Bauters, F. & Fenaux, P. (1995) Cytogenetic analysis has strong independent prognostic value in de novo myelodysplastic syndromes and can be incorporated in a new scoring system: a report of 408 cases. Leukemia, 7, 1315-1323.
35. Mufti, G.J., Stevens, J.R., Oscier, D.G., Hamblin, T.J. & Machin, D. (1985) Myelodysplastic syndromes: a scoring system with prognostic significance. British Journal of Haematology, 59, 425-433.
36. Nisse, C., Lorthois, C., Dorp, V., Eloy, E., Haguenoer, J., M. & Fenaux, P. (1995) Exposure to occupational and enivronnemental factors in myelodysplastic syndromes: preliminary results of case-control study. Leukemia, 9, 693-699.
37. Oscier, D.G. (1987) Myelodysplastic syndromes. Clinical Haematology, 1, 389-426.
38. Ossenkoppele, G.J., Verhoef, G.E.G., van der Holt, B., Verdonck, L.F., Vellenga, E., Sonneveld, P., van der Lelie, J., Wijermans, P.W. & Löwenberg, B. (1995) Randomized phase II study on the value of G-CSF (filgrastim) in combination with stazndard induction chemotherapy in myelodysplastic syndromes (MDS). (Abstract). Blood, 86, (Suppl. 1), 338a.
39. Ruutu, T., Hänninen, A., Järventie, G., Koistinen, P., Koivunen, E., Kätka, K., Nousiainen, T., Pelliniemi, T.T., Remes, K., Timonen, T., Volin, L. & Elonen, E. (1994) Intensive treatment of poor prognosis myelodysplastic syndromes (MDS) and acute myeloid leukaemia subsequent to MDS with idarubicin and cytarabine. (Abstract). British Journal of Haematology, 87, (Suppl. 1), 19.
40. Sanz, G.F., Sanz, M.A. & Vallespi, T. (1989) Two regression models and a scoring system for predicting survival and planning treatment in myelodysplastic syndromes: a multivariate analysis of prognostic factors in 370 patients. Blood, 74, 395-408.
41. Solary, E., Witz, B., Caillot, D., Moreau, P., Desablens, B., Cahn, J.Y., Sadoun, A., Pignon, B., Berthou, C., Maloisel, F., Guyotat, D., Casassus, P., Ifrah, N., Lamy, Y., Audhuy, B., Colombat, P. & Harousseau, J.L. (1996) Combination of quinine as a potential reversing agent with mitoxantrone and cytarabine for the treatment of acute leukemias: a randomized multicenter study. Blood, 88, 1198-1205.
42. Steinmetz, H.T., Staib, P., Glasmacher, A., Neufang, A., Katay, I., Diehl, V. & Dias Wickramanayake, P. (1996) Phase II study of idarubicin, fludarabine, Ara-C, and G-CSF (Ida-FLAG) for treatment of refractory, relapsed and secondary acute myeloid leukaemia (Abstract). British Journal of Haematology, 93, (Suppl. 2), 219.
43. Sutton, L., Leblond, V.L., Maignan, C., Jouet, J.P., Kuentz, M., Gluckman, E., Blaise, D., Marit, G., Attal, M., Troussard, X., Bordigoni, P., Cahn, J.Y. & Ribaud, P. (1991) Bone marrow transplantion for myelodysplastic syndrome and secondary leukemia: outcome of 86 patients. Bone Marrow Transplantation, 7, (Suppl. 2), 39.
44. Wattel, E., Solary, E., Caillot, D., Dreyfus, F., Brion, A., Mahé, B., Hoang-Ngoc, L., Maloisel, F., Guerci, A., Rochant, H., Gratecos, N., Sadoun, A., Stamatoullas, A., Casassus, P., Janvier, M., Stoppa, A.M., Desablens, B., Fegeux, N., Ifrah, N., Abgrall, J.P., Guyotat, D., Dupriez, B., Peny, A.M., Brice, P., Pignon, B., Leporrier, M., Lepelley, P. & Fenaux, P. (1996a) Quinine improves results of intensive chemotherapy in myelodysplastic syndromes (MDS) expressing p glycoprotein (PGP). Blood, 88, (Suppl. 1), 1807.
45. Wattel, E., Solary, E., Caillot, D., Dreyfus, F., Brion, A., Mahé, B., Jouet, J.P., Hoang-Ngoc, L., Maloisel, E. Guerci, A., Rochant, H., Gratecos, N., Sadoun, A., Stamatoullas, A., Casassus, P., Janvier, M., Stoppa, A.M., Desablens, B., Fegeux, N., Guyotat, D., Brice, P., Lepelley, P. & Fenaux, P. (1996b) Prospective study of autologous bone marrow (ABMT) or peripheral blood stem cell (ABSCT) transplantation after intensive chemotherapy in myelodysplastic syndromes (MDS). Blood, 88, (Suppl. 1), 507.